Literature DB >> 11524712

Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

X Zhao1, K Drlica.   

Abstract

Studies with fluoroquinolones have led to a general method for restricting the selection of antibiotic-resistant mutants. The strategy is based on the use of antibiotic concentrations that require cells to obtain 2 concurrent resistance mutations for growth. That concentration has been called the "mutant prevention concentration" (MPC) because no resistant colony is recovered even when >10(10) cells are plated. Resistant mutants are selected exclusively within a concentration range (mutant selection window) that extends from the point where growth inhibition begins, approximated by the minimal inhibitory concentration, up to the MPC. The dimensions of the mutant selection window can be reduced in a variety of ways, including adjustment of antibiotic structure and dosage regimens. The window can be closed to prevent mutant selection through combination therapy with > or =2 antimicrobial agents if their normalized pharmacokinetic profiles superimpose at concentrations that inhibit growth. Application of these principles could drastically restrict the selection of drug-resistant pathogens.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11524712     DOI: 10.1086/321841

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  110 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Mutant prevention concentration of gemifloxacin for clinical isolates of Streptococcus pneumoniae.

Authors:  Glen T Hansen; Kelli Metzler; Karl Drlica; Joseph M Blondeau
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

Review 3.  Dosing regimen matters: the importance of early intervention and rapid attainment of the pharmacokinetic/pharmacodynamic target.

Authors:  Marilyn N Martinez; Mark G Papich; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

4.  Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical Candida glabrata Isolates.

Authors:  Pilar Escribano; Jesús Guinea; María Ángeles Bordallo-Cardona; Laura Judith Marcos-Zambrano; Carlos Sánchez-Carrillo; Elia Gómez G de la Pedrosa; Rafael Cantón; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

5.  Nevirapine plasma exposure affects both durability of viral suppression and selection of nevirapine primary resistance mutations in a clinical setting.

Authors:  D González de Requena; S Bonora; S Garazzino; M Sciandra; A D'Avolio; R Raiteri; R Marrone; M Boffito; F G De Rosa; A Sinicco; G Di Perri
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Quinolone-resistant Haemophilus influenzae: determination of mutant selection window for ciprofloxacin, garenoxacin, levofloxacin, and moxifloxacin.

Authors:  Xinying Li; Noriel Mariano; James J Rahal; Carl M Urban; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2004-11       Impact factor: 5.191

7.  Mutant prevention concentrations of ABT-492, levofloxacin, moxifloxacin, and gatifloxacin against three common respiratory pathogens.

Authors:  Elizabeth D Hermsen; Laurie B Hovde; George N Konstantinides; John C Rotschafer
Journal:  Antimicrob Agents Chemother       Date:  2005-04       Impact factor: 5.191

8.  beta-Lactam MICs correlate poorly with mutant prevention concentrations for clinical isolates of Acinetobacter spp. and Pseudomonas aeruginosa.

Authors:  Juliana Gugel; Andrea Dos Santos Pereira; Antônio C C Pignatari; Ana C Gales
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

9.  Antibiotic pharmacodynamics and bacterial resistance: usefulness of in vitro models.

Authors:  Stephen H Zinner; Alexander Firsov
Journal:  Curr Infect Dis Rep       Date:  2007-05       Impact factor: 3.725

10.  Validation of the mutant selection window hypothesis with fosfomycin against Escherichia coli and Pseudomonas aeruginosa: an in vitro and in vivo comparative study.

Authors:  Ai-Jun Pan; Qing Mei; Ying Ye; Hong-Ru Li; Bao Liu; Jia-Bin Li
Journal:  J Antibiot (Tokyo)       Date:  2016-10-19       Impact factor: 2.649

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.